neurology
Neurodegenerative disorders

Alzheimer’s disease: why insulin is a new suspect

Johnson and Johnson recently announced that it was halting a clinical trial for a new Alzheimer’s drug after safety issues emerged. This latest failure adds to the dozens of large, costly clinical trials that have shown no effect in treating this devastating disease. The growing list of failures should give us pause for thought – have we ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic